HCA vs UHS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: UHS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCA and UHS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCA and UHS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Its strategy centers on building dense local networks in growing Sun Belt and suburban markets, where controlling a large share of care lets it negotiate better rates with commercial insurers, recruit physicians, and spread fixed costs. In the first quarter of 2026 HCA reported revenue of about $19.1 billion, up roughly 4% year over year, with net income near $1.6 billion and diluted EPS of about $7.15. Equivalent admissions rose modestly and revenue per admission grew faster, and the company reaffirmed full-year 2026 guidance of roughly $76.5 billion to $80.0 billion in revenue and $15.55 billion to $16.45 billion in adjusted EBITDA.

Full HCA guide

Universal Health Services is a Pennsylvania-based healthcare company that owns and operates acute care hospitals, behavioral health facilities, outpatient centers, and ambulatory surgery locations across the United States and in the United Kingdom. Its two core segments are acute care, which covers general hospitals and emergency and surgical services, and behavioral health, which spans inpatient psychiatric and addiction treatment facilities where UHS is one of the largest operators in the country. The company also expanded its virtual behavioral health reach through the acquisition of Talkspace.

Full UHS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HCA drivers: Scale and local-market density; Outpatient and ambulatory expansion.
• UHS drivers: Behavioral health scale; Acute care volumes and pricing.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is reimbursement and health-care policy. For UHS, the largest risks are tied to government reimbursement.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HCA if you believe its drivers more; UHS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCA and UHS guides.

HCA. Figures are approximate and tied to the asOf date; verify live numbers before acting. HCA is generally valued as a steady, cash-generative operator rather than a high-growth stock, so its multiple reflects reimbursement stability and buyback-driven per-share growth more than rapid revenue expansion. The biggest variable is policy: the 2026 guidance already bakes in an ACA-subsidy and Medicaid hit that management is partly offsetting, so how those headwinds actually land matters more to the earnings picture than the headline multiple.

UHS. UHS trades at a notably low price-to-earnings multiple, in the high single digits, well below broader market averages and its own longer-run history. That reflects investor caution around reimbursement and policy exposure rather than weak results, since revenue grew about 9.7 percent in 2025 and momentum carried into 2026.

Headline figures (approximate, Jul 2026): HCA shows revenue (q1 2026) ~$19.1 billion, up ~4% year over year, full-year 2026 revenue guidance ~$76.5 billion to $80.0 billion (reaffirmed), adjusted ebitda guidance (2026) ~$15.55 billion to $16.45 billion, net income (q1 2026) ~$1.6 billion, or ~$7.15 per diluted share; UHS shows revenue (fy2025) ~$17.4B, net income attributable to uhs (fy2025) ~$1.49B, diluted eps (fy2025) ~$23.10, market cap ~$10B.

HCA and UHS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HCA and UHS exposure against your real portfolio. It is not an investment adviser.